Ubrogepant Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

It is formulated by 1 pharmaceutical company such as ABBVIE. It is marketed under 1 brand name, including UBRELVY. Available in 2 different strengths, such as 50MG, 100MG, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"98221","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"82dda10773144ee7a213","publication_number":"US9499545B2","cleaned_patent_number":"9499545","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-10","publication_date":"2016-11-22","legal_status":"Granted"} US9499545B2 Molecular Formulation 22 Nov, 2016 Granted 10 Nov, 2031
{"application_id":"98277","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"82dda10773144ee7a213","publication_number":"US9833448B2","cleaned_patent_number":"9833448","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-10","publication_date":"2017-12-05","legal_status":"Granted"} US9833448B2 05 Dec, 2017 Granted 10 Nov, 2031
{"application_id":"98275","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"82dda10773144ee7a213","publication_number":"US8754096B2","cleaned_patent_number":"8754096","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-07-19","publication_date":"2014-06-17","legal_status":"Granted"} US8754096B2 Molecular Formulation 17 Jun, 2014 Granted 19 Jul, 2032
{"application_id":"98276","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"82dda10773144ee7a213","publication_number":"US8912210B2","cleaned_patent_number":"8912210","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-12-23","publication_date":"2014-12-16","legal_status":"Granted"} US8912210B2 Molecular Formulation 16 Dec, 2014 Granted 23 Dec, 2033
{"application_id":"242163","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"","publication_number":"US12310953B2","cleaned_patent_number":"12310953","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-30","publication_date":"2025-05-27","legal_status":"Granted"} US12310953B2 Formulation 27 May, 2025 Granted 30 Jan, 2035
{"application_id":"98294","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"fe26ba9df10246468898","publication_number":"US10117836B2","cleaned_patent_number":"10117836","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-30","publication_date":"2018-11-06","legal_status":"Granted"} US10117836B2 Formulation 06 Nov, 2018 Granted 30 Jan, 2035
{"application_id":"98322","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"fe26ba9df10246468898","publication_number":"US11925709B2","cleaned_patent_number":"11925709","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-30","publication_date":"2024-03-12","legal_status":"Granted"} US11925709B2 Formulation 12 Mar, 2024 Granted 30 Jan, 2035
{"application_id":"139441","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"","publication_number":"US12168004B2","cleaned_patent_number":"12168004","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-30","publication_date":"2024-12-17","legal_status":"Granted"} US12168004B2 Formulation 17 Dec, 2024 Granted 30 Jan, 2035
{"application_id":"164561","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"","publication_number":"US12220408B2","cleaned_patent_number":"12220408","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-30","publication_date":"2025-02-11","legal_status":"Patented Case"} US12220408B2 Formulation 11 Feb, 2025 Patented Case 30 Jan, 2035
{"application_id":"139440","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"","publication_number":"US12194030B2","cleaned_patent_number":"12194030","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-12-22","publication_date":"2025-01-14","legal_status":"Granted"} US12194030B2 14 Jan, 2025 Granted 22 Dec, 2041
{"application_id":"130743","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"","publication_number":"US12070450B2","cleaned_patent_number":"12070450","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-12-22","publication_date":"2024-08-27","legal_status":"Granted"} US12070450B2 27 Aug, 2024 Granted 22 Dec, 2041
{"application_id":"116761","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"4c52bf4cc9ae49128cea","publication_number":"US11857542B2","cleaned_patent_number":"11857542","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-12-22","publication_date":"2024-01-02","legal_status":"Granted"} US11857542B2 02 Jan, 2024 Granted 22 Dec, 2041
{"application_id":"116758","ingredient":"UBROGEPANT","trade_name":"UBRELVY","family_id":"d2f4f2a5b6054329bd60","publication_number":"US11717515B2","cleaned_patent_number":"11717515","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-12-22","publication_date":"2023-08-08","legal_status":"Granted"} US11717515B2 08 Aug, 2023 Granted 22 Dec, 2041

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Ubrogepant

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.